Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : F. Hoffmann-La Roche Ltd
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Study of Alectinib versus Pemetrexed or Docetaxel in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer
To evaluate and compare between treatment groups the efficacy of alectinib versus chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) wh...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A single arm Phase IV study to assess efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-fluorouracil/folinic acid regimens as first line treatment for patients with metastatic colorectal cancer
To determine the efficacy of bevacizumab in combination with irinotecan and infusional 5-fluorouracil plus folinic acid based regimens as compared with historical controls, based on progression free s...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy
To evaluate whether maintenance therapy with bevacizumab plus capecitabine, compared to bevacizumab alone, can further increase Progression-Free Survival (PFS) in patients showing objective response o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING LUNG CANCER RESECTION AND CHEMOTHERAPY FOR EARLY STAGE LUNG CANCER
To evaluate the efficacy of 16 cycles of atezolizumab treatment compared with best supportive care as measured by disease-free survival (DFS) as assessed by the investigator.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients
The primary objective of the study is to evaluate prospectively the efficacy of oseltamivir in the seasonal prophylaxis of influenza as measured by the relative incidence of laboratory confirmed clini...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic disease
The primary objectives for this study are as follows: • To explore the efficacy of T-DM1 compared with the combination of trastuzumab and docetaxel in patients with HER2-positive, unresectable, locall...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
The primary objective is to determine the efficacy of taspoglutide based on glycemic control (as assessed by HbA1c) compared with placebo in drug-naïve patients with type 2 diabetes after 24 weeks of ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A randomized, multicenter, open-label study evaluating two different doses of pertuzumab in patients with HER2-positive advanced gastric cancer
• To estimate the minimum (trough) pertuzumab concentration (Cmin) at Day 43 for two dose levels of pertuzumab in order to identify a dose that produces a steady-state Cmin of ≥ 20 μg/mL in 90% of p...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Multi-center, randomized, double-blind, 5-arm parallel group, placebo controlled 4 week study to investigate the safety, tolerability and efficacy of two doses each (near to maximum tolerated dose and lower dose) of RO5093151 administered twice daily (BID regimen) and RO5027838 administered once daily (QD regimen) in patients with type 2 diabetes mellitus on a stable dose of metformin
To measure the effect of the two 11β-HSD1 inhibitors RO5093151 and RO5027838 on mean daily plasma glucose (change from baseline at Week 4) in type 2 diabetic patients treated with a stable dose of met...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of Pegasys 180 µg plus Copegus 1000 or 1200 mg to the Currently Approved Combination of Pegasys 180 µg plus Copegus 800 mg in Interferon-naïve Patients with Chronic Hepatitis C Genotype 1 virus infection coinfected with human immunodeficiency virus (HIV-1)
Primary Efficacy • To compare the efficacy of treatment with Copegus (ribavirin (RBV)) 1000 or 1200 mg in combination with Pegasys (peginterferon alfa-2a (PEG-IFN alfa-2a)) 180 µg to the approved regi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant